Τίτλος:
Assessment of Early Markers of Cardiovascular Risk in Polycystic Ovary Syndrome.
Περίληψη:
Polycystic ovary syndrome (PCOS) is a heterogeneous syndrome, with long-term sequelae from birth to senescence. The long-term effects of PCOS are attributed to several metabolic aberrations ensuing the syndrome. In a systematic review of literature regarding the cardiovascular risk factors that accompany PCOS, we found that macrovascular function has been assessed by flow-mediated dilatation (FMD), microvascular function by venous occlusion plethysmography (VOP), and arterial structure by ultrasonographic assessment of intima-media thickness (IMT) usually of the carotid artery. Contradictory results have been reported; however, in most studies, endothelial dysfunction, an early marker of atherosclerosis assessed either by haemodynamic methods such as FMD or by biochemical methods such as endothelin-1 levels, was found to be impaired. VOP is a less-studied method, with few indices altered. IMT was found to be altered in most of the included studies, but the population was more heterogeneous. Inflammatory markers, including C-reactive protein, were also found to be altered in most studies. On the other hand, a number of interventions have been shown beneficial for the markers of cardiovascular risk, in the context of insulin-sensitizers. However, other interventions such as oral contraceptive pills or statins did not consistently show a similar beneficial effect. In summary, the early identification and eventual treatment of cardiovascular clinical and biochemical risk factors may be used in clinical practice to prevent potential 'silent' triggers of cardiovascular disease.
Συγγραφείς:
Alexandraki, Krystallenia I.
Kandaraki, Eleni A.
Poulia, Kalliopi-Anna
Piperi, Christina
Papadimitriou, Eirini
Papaioannou, Theodoros G.
Περιοδικό:
TouchREVIEWS in endocrinology
Λέξεις-κλειδιά:
insulin resistance, metformin, arterial stiffness, Flow-mediated dilatation, inositols, insulin sensitizers, intima-media thickness, nitrate-mediated dilatation, polycystic ovary syndrome, spironolactone
DOI:
10.17925/EE.2021.17.1.37
